Literature DB >> 18351324

Cognitive performance in neurokinin 3 receptor knockout mice.

R E Nordquist1, M Delenclos, T M Ballard, H Savignac, M Pauly-Evers, L Ozmen, W Spooren.   

Abstract

RATIONALE: The neurokinin 3 (NK(3)) receptor is a novel target under investigation for improvement of the symptoms of schizophrenia due to its ability to modulate dopaminergic signaling. However, research on effects of NK(3) antagonism with animal models has been hindered because of species differences in the receptor between humans, rats, and mice.
OBJECTIVES: The aim of the present study is to further knowledge on the role of NK(3) in cognitive functioning by testing the effect of knockout of the NK(3) receptor on tests of working memory, spatial memory, and operant responding.
MATERIALS AND METHODS: NK(3) knockout mice generated on a C57Bl/6 background were tested in delayed matching to position (DMTP), spontaneous alternation, Morris water maze, and active avoidance tasks.
RESULTS: NK(3) knockout mice showed better performance in the DMTP task, though not delay dependently, which points to an effect on operant performance but not on working memory. No differences were seen between the groups in spontaneous alternation, another indication that working memory is not affected in NK(3) knockouts. There was no impairment in knockout mice in Morris water maze training, and the mice also showed faster response latency in the active avoidance task during training.
CONCLUSIONS: Collectively, these results support a role for the NK(3) receptor in performance of operant tasks and in spatial learning but not in working memory.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18351324     DOI: 10.1007/s00213-008-1119-6

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  33 in total

1.  Air and shock two-way shuttlebox avoidance in C57BL/6J and 129X1/SvJ mice.

Authors:  Matthew G Clark; Sam Vasilevsky; Todd M Myers
Journal:  Physiol Behav       Date:  2003-01

2.  Neurokinin agonists differentially affect A9 and A10 dopamine cells in the rat.

Authors:  P Overton; P J Elliott; R M Hagan; D Clark
Journal:  Eur J Pharmacol       Date:  1992-03-17       Impact factor: 4.432

Review 3.  Modern antipsychotic drugs: a critical overview.

Authors:  David M Gardner; Ross J Baldessarini; Paul Waraich
Journal:  CMAJ       Date:  2005-06-21       Impact factor: 8.262

Review 4.  Opinion: NK3 receptor antagonists: the next generation of antipsychotics?

Authors:  Will Spooren; Claus Riemer; Herbert Meltzer
Journal:  Nat Rev Drug Discov       Date:  2005-12       Impact factor: 84.694

5.  Sertindole, in contrast to clozapine and olanzapine, does not disrupt water maze performance after acute or chronic treatment.

Authors:  Michael Didriksen; Mads Kreilgaard; Jørn Arnt
Journal:  Eur J Pharmacol       Date:  2006-05-20       Impact factor: 4.432

6.  Neurokinin receptor mRNA localization in human midbrain dopamine neurons.

Authors:  C J Whitty; M A Paul; M J Bannon
Journal:  J Comp Neurol       Date:  1997-06-09       Impact factor: 3.215

7.  Performance of F2 B6x129 hybrid mice in the Morris water maze, latent inhibition and prepulse inhibition paradigms: Comparison with C57Bl/6J and 129sv inbred mice.

Authors:  Natasja de Bruin; Michel Mahieu; Tarah Patel; Roland Willems; Anne Lesage; Anton Megens
Journal:  Behav Brain Res       Date:  2006-06-09       Impact factor: 3.332

8.  Impairment on the hippocampal-dependent virtual Morris water task in schizophrenia.

Authors:  Faith M Hanlon; Michael P Weisend; Derek A Hamilton; Aaron P Jones; Robert J Thoma; Mingxiong Huang; Kimberly Martin; Ronald A Yeo; Gregory A Miller; Jose M Cañive
Journal:  Schizophr Res       Date:  2006-07-14       Impact factor: 4.939

9.  Genetic and behavioral differences among five inbred mouse strains commonly used in the production of transgenic and knockout mice.

Authors:  G W M Bothe; V J Bolivar; M J Vedder; J G Geistfeld
Journal:  Genes Brain Behav       Date:  2004-06       Impact factor: 3.449

10.  Involvement of dopamine receptors in beneficial effects of tachykinins on scopolamine-induced impairment of alternation performance in mice.

Authors:  M Ukai; N Shinkai; T Kameyama
Journal:  Eur J Pharmacol       Date:  1998-05-29       Impact factor: 4.432

View more
  5 in total

1.  Characterization of RO4583298 as a novel potent, dual antagonist with in vivo activity at tachykinin NK₁ and NK₃ receptors.

Authors:  P Malherbe; F Knoflach; M C Hernandez; T Hoffmann; P Schnider; R H Porter; J G Wettstein; T M Ballard; W Spooren; L Steward
Journal:  Br J Pharmacol       Date:  2011-02       Impact factor: 8.739

2.  Uncovering novel reproductive defects in neurokinin B receptor null mice: closing the gap between mice and men.

Authors:  Jasmine J Yang; Claudia S Caligioni; Yee-Ming Chan; Stephanie B Seminara
Journal:  Endocrinology       Date:  2012-01-17       Impact factor: 4.736

3.  TAC3 and TACR3 mutations in familial hypogonadotropic hypogonadism reveal a key role for Neurokinin B in the central control of reproduction.

Authors:  A Kemal Topaloglu; Frank Reimann; Metin Guclu; Ayse Serap Yalin; L Damla Kotan; Keith M Porter; Ayse Serin; Neslihan O Mungan; Joshua R Cook; Sazi Imamoglu; N Sema Akalin; Bilgin Yuksel; Stephen O'Rahilly; Robert K Semple
Journal:  Nat Genet       Date:  2008-12-11       Impact factor: 38.330

4.  TACR3 mutations disrupt NK3R function through distinct mechanisms in GnRH-deficient patients.

Authors:  Sekoni D Noel; Ana Paula Abreu; Shuyun Xu; Titilayo Muyide; Elena Gianetti; Cintia Tusset; Jessica Carroll; Ana Claudia Latronico; Stephanie B Seminara; Rona S Carroll; Ursula B Kaiser
Journal:  FASEB J       Date:  2013-12-27       Impact factor: 5.191

5.  Kisspeptin restores pulsatile LH secretion in patients with neurokinin B signaling deficiencies: physiological, pathophysiological and therapeutic implications.

Authors:  Jacques Young; Jyothis T George; Javier A Tello; Bruno Francou; Jerome Bouligand; Anne Guiochon-Mantel; Sylvie Brailly-Tabard; Richard A Anderson; Robert P Millar
Journal:  Neuroendocrinology       Date:  2012-02-24       Impact factor: 4.914

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.